New psoriasis drug QL2106 goes Head-to-Head with tremfya in major trial
NCT ID NCT07511647
First seen Apr 24, 2026 · Last updated May 23, 2026 · Updated 7 times
Summary
This study tests a new injection called QL2106 against the approved drug Tremfya for people with moderate to severe plaque psoriasis. About 318 adults will be randomly assigned to receive either QL2106 or Tremfya, and researchers will compare how well each clears skin symptoms after 16 weeks. The goal is to see if QL2106 works as well and is as safe as the current treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLAQUE PSORIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.